COMPANY PROFILE

Edico Genome

Edico Genome is the developer of DRAGEN, the world's first Bio-IT processor for analyzing Next Generation Sequencing data.

San Diego, United StatesFounded 2013Biotech & Life Sciences

Valuation $100–250M Last recorded · 2017

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Edico Genome

Edico Genome operates in the genomic testing and sequencing industry, focusing on providing advanced solutions for oncology. The company serves healthcare providers, research institutions, and pharmaceutical companies by offering comprehensive genomic profiling from both blood and tissue samples. Edico Genome's business model revolves around selling high-precision sequencing instruments, reagents, and software tools that enable accurate measurement and analysis of genetic data. Revenue is generated through the sale of these products, as well as through partnerships and collaborations that expand patient access to genomic testing. The company aims to transform cancer treatment by offering tools that predict cancer risk, identify targets for breast cancer, and facilitate liquid biopsies. Edico Genome's market includes the broader healthcare and life sciences sectors, with a particular emphasis on oncology research and personalized medicine.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2013
Headquarters: San Diego, United States
Open positions: None listed
Dealroom signal: 21.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Analytics, Biotechnology, DNA, Genetics and genomics, Sequencing, Processor, Genome Engineering, Biotech and Pharma, Hard Tech
Technology: Big Data
Business model: SaaS
Client focus: b2b
Links: Website X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	May 2018	$0	—	Illumina	—
SERIES B✓Equity / VC	May 2017	$22M	$88M	Qualcomm Ventures · Dell Technologies Capital · Axon Ventures	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Edico Genome website traffic

Latest recorded traffic for Edico Genome is 190 monthly website visits, up 111.1% over the last three months.

Latest monthly visits190 3-month web change+111.1%

Monthly website visitsJan 2017–Dec 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GIGenomics Medicine IrelandExamines the relationship between genetics, health and disease	Dublin, Ireland	Closed	—	$40M	$160M
BABasepairBasepair \| NGS Analysis Simplified	New York City, United States	Operational
BIBiomodalSimultaneous genetic and epigenetic sequencing from single samples	Cambridge, United Kingdom	Operational
ARArpeggiAnalysis and data management for medical industry	Austin, United States	Acquired
DLDante LabsDante Labs is transforming genetics	New York City, United States	Operational
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational
CECelmatixHarnessing the power of data and genomics to optimize medical decisions about fertility.	New York City, United States	Operational
NGNucleus GenomicsOffers an all-in-one DNA health test, combining whole-genome sequencing with lifestyle factors to deliver the comprehensive insights into health and well-being	New York City, United States	Operational